08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
When I started my law practice, I started to look at what the competition was doing and I decided to...
Read More >
In this episode of Trekking Through Compliance, we consider the episode The Cloud Miners which aired...
Read More >
Last week, U.S. District Court Judge Tanya S. Chutkan ruled that the EEOC may not discontinue its pa...
Read More >
Seyfarth Synopsis: The Western District of New York, in Horn v. Medical Marijuana, Inc., et al., iss...
Read More >
It's difficult enough to keep on top of the news at the moment – not to mention the raft of recent ...
Read More >
The South Carolina Supreme Court just ruled that the state will no longer recognize common-law marri...
Read More >